Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company, presented encouraging findings from their ongoing ARCHER trial at the American Society of Retina Specialists (ASRS) 2023 Annual Meeting. The results showcased the potential of Annexon’s ANX007 in providing vision protection for patients with geographic atrophy (GA), a type of age-related macular degeneration.
The data presented in the oral presentation, titled Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration with Intravitreal ANX007: Results of the ARCHER Study, highlighted ANX007’s distinct neuroprotective mechanism of action and its ability to consistently prevent vision loss.
Jeffrey S. Heier, M.D., director of the Retina Service and Retina Research at Ophthalmic Consultants of Boston and an investigator in the ARCHER trial, emphasized the significance of vision preservation for individuals living with GA worldwide. He expressed excitement about ANX007’s potential to preserve vision in a broad range of patients, considering its promising neuroprotective mechanism of action.
Recent topline data from May 2023 already demonstrated that ANX007 delivered statistically significant protection against vision loss in patients with GA. The measurement utilized in the study was best corrected visual acuity (BCVA), where a loss of 15 letters or more is considered a functional endpoint. ANX007 exhibited dose-dependent protection across multiple measures, including low luminance visual acuity (LLVA) and low luminance visual deficit (LLVD).
During the ASRS presentation, Annexon provided additional analyses that evaluated the impact of ANX007 treatment on both BCVA and the area of GA lesions. These results further validated the potential efficacy of ANX007 in preserving visual function in patients with GA.
By reaffirming ANX007’s neuroprotective properties and its ability to prevent vision loss, Annexon’s research represents a promising advancement in the field of geographic atrophy treatment. As the ARCHER trial continues, Annexon remains focused on developing complement-based medicines to address autoimmune, neurodegenerative, and ophthalmic disorders.
The successful presentation at the ASRS 2023 Annual Meeting brings hope to millions of people worldwide and serves as a significant step forward in the quest to preserve vision for those living with GA. As researchers and physicians continue to explore the potential of ANX007, the future looks brighter for patients battling geographic atrophy.
